Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) – Oppenheimer cut their FY2021 earnings per share (EPS) estimates for shares of Aptose Biosciences in a report issued on Wednesday, March 27th, according to Zacks Investment Research. Oppenheimer analyst M. Biegler now expects that the biotechnology company will post earnings of ($0.59) per share for the year, down from their previous estimate of ($0.54). Oppenheimer has a “Outperform” rating and a $6.00 price target on the stock. Oppenheimer also issued estimates for Aptose Biosciences’ FY2022 earnings at ($0.73) EPS.
A number of other research analysts also recently commented on the company. Zacks Investment Research downgraded Aptose Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, January 8th. HC Wainwright set a $9.00 price target on Aptose Biosciences and gave the company a “buy” rating in a research note on Friday, March 22nd. Citigroup started coverage on Aptose Biosciences in a research note on Friday, January 25th. They issued an “outperform” rating and a $6.00 price target for the company. Finally, Royal Bank of Canada started coverage on Aptose Biosciences in a research note on Friday, March 1st. They issued an “outperform” rating and a $6.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Aptose Biosciences presently has an average rating of “Buy” and an average target price of $5.71.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.01).
Institutional investors have recently added to or reduced their stakes in the company. Noven Financial Group Inc. acquired a new position in shares of Aptose Biosciences in the fourth quarter valued at approximately $27,000. Geode Capital Management LLC acquired a new position in shares of Aptose Biosciences in the fourth quarter valued at approximately $33,000. Boston Advisors LLC acquired a new position in shares of Aptose Biosciences in the first quarter valued at approximately $36,000. Citadel Advisors LLC acquired a new position in shares of Aptose Biosciences in the third quarter valued at approximately $125,000. Finally, Patriot Financial Group Insurance Agency LLC increased its stake in shares of Aptose Biosciences by 11.4% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 5,890 shares during the period. 7.68% of the stock is owned by institutional investors.
In other Aptose Biosciences news, CFO Gregory K. Chow bought 15,000 shares of the stock in a transaction on Wednesday, March 13th. The stock was purchased at an average price of $1.75 per share, with a total value of $26,250.00. Following the completion of the purchase, the chief financial officer now owns 122,014 shares in the company, valued at $213,524.50. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Erich Platzer sold 20,000 shares of the business’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $2.19, for a total value of $43,800.00. The disclosure for this sale can be found here. In the last three months, insiders have acquired 35,000 shares of company stock valued at $63,750.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Further Reading: The risks of owning bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.